PEP005 topical ingenol mebutate gel: Phase IIb started

Peplin began a double-blind, placebo-controlled, international Phase IIb trial of PEP005. Patients will apply one of 3 concentrations (0.005%, 0.010% or 0.015%) to a 25 cm 2 affected area on the face ...